REFERENCES
1. Hoogeveen RC, Ballantyne CM. Residual cardiovascular risk at low LDL: remnants, lipoprotein(a), and inflammation. Clin Chem. 2021;67:143-53.
2. Mensah GA, Arnold N, Prabhu SD, Ridker PM, Welty FK. Inflammation and cardiovascular disease: 2025 ACC scientific statement: a report of the American College of Cardiology. J Am Coll Cardiol. 2026;87:1381-404.
3. Mastrangelo A, Robles-Vera I, Mañanes D, et al. Imidazole propionate is a driver and therapeutic target in atherosclerosis. Nature. 2025;645:254-61.
4. Molinaro A, Nemet I, Bel Lassen P, et al. Microbially produced imidazole propionate is associated with heart failure and mortality. JACC Heart Fail. 2023;11:810-21.
5. Fan J, Kitajima S, Watanabe T, et al. Rabbit models for the study of human atherosclerosis: from pathophysiological mechanisms to translational medicine. Pharmacol Ther. 2015;146:104-19.
6. Jia L, Qu P, Zhao Y, et al. Tripeptide DT-109 (Gly-Gly-Leu) attenuates atherosclerosis and vascular calcification in nonhuman primates. Sig Transduct Target Ther. 2025;10:122.
7. Bousquet P, Hudson A, García-Sevilla JA, Li J. Imidazoline receptor system: the past, the present, and the future. Pharmacol Rev. 2020;72:50-79.
